Heinz Ludwig, MD, of the Wilhelminen Cancer Research Institute, Vienna, Austria gives an overview of why the management of infections is extremely important for myeloma patients. Unfortunately, approximately 20% of myeloma patients die because of an infection and some of these infections can be prevented. He explains why immunosuppression results in the increased risk of infection and how this varies during the treatment journey. Recorded at the 2017 European Multiple Myeloma Academy (EMMA) in Vienna, Austria. This program was sponsored by Celgene through an unrestricted educational grant to Video Journal of Hematological Oncology.